BiotechTube
Achelios Therapeutics

Achelios Therapeutics

Durham, United States· Est.
achelios.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Achelios Therapeutics is a private, pre-revenue biotech founded in 2016 and based in Durham, North Carolina. The company is developing 'New Therapeutic Entities' (NTEs)—topical formulations designed to deliver large quantities of NSAIDs through the skin directly to the site of pain and inflammation. Its lead program, TOPOFEN™, appears to be in clinical development for conditions like TMJ pain and arthralgia, aiming to provide localized relief with potentially reduced systemic side effects compared to oral NSAIDs.

PainInflammationMusculoskeletal Disorders

Technology Platform

Proprietary transdermal delivery platform formulating 'New Therapeutic Entities' (NTEs) to enhance permeation of NSAIDs across human skin for targeted tissue delivery.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

Large and growing chronic pain market with unmet need for effective, non-systemic therapies.
TMJ disorder represents a specific niche with limited treatment options.
Successful platform validation could be applied to multiple NSAIDs and other drug classes for localized delivery.

Risk Factors

High risk of clinical failure to demonstrate efficacy superior to existing topical products.
Dependence on securing additional funding to advance through clinical trials.
Intense competition in the topical analgesic market from both generic and branded products.

Competitive Landscape

Competes against other topical NSAIDs (e.g., Voltaren gel), systemic pain medications, and novel pain therapies. Differentiation hinges on proving superior drug penetration and localized efficacy. May also compete with intra-articular injections for joint-specific conditions.

More companies in Small Molecule Drugs →More companies in United States →